@prefix biolink: .
@prefix ns1: .
@prefix this: .
@prefix sub: .
@prefix schema: .
@prefix np: .
@prefix xsd: .
@prefix rdfs: .
@prefix orcid: .
@prefix nkg: .
@prefix dct: .
@prefix rdf: .
@prefix npx: .
@prefix prov: .
sub:Head {
this: np:hasAssertion sub:assertion;
np:hasProvenance sub:provenance;
np:hasPublicationInfo sub:pubinfo;
a np:Nanopublication .
}
sub:assertion {
biolink:category biolink:Disease .
sub:association rdf:object ;
rdf:predicate biolink:treats;
rdf:subject ;
a rdf:Statement;
rdfs:label "Paliperidone is FDA-approved for schizophrenia aged 12-17. However, the pharmacologic portfolio, extrapolation from adult studies, and the long track record of the parent drug, risperidone in child/adolescent psychiatric (CAP) population might expand its therapeutic potential. An 8-week open-label study [9] examined paliperidone monotherapy for acute mania, mixed, or hypomanic episode in pediatric patients (n = 15, 6–17 years of age) with bipolar spectrum disorders. At the end of follow-up period, 11 subjects (73%) completed the study; treatment with paliperidone was associated with a 60% response rate (50% decrease in the Young Mania Rating Scale) and 40% remission (YMRS <12)";
biolink:has_population_context sub:cohort;
biolink:provided_by ;
biolink:publications ;
biolink:relation nkg:OffLabelIndication .
sub:cohort rdfs:label "Children and adolescents";
schema:requiredMaxAge "17";
schema:requiredMinAge "12";
biolink:category biolink:Cohort .
biolink:category biolink:Drug .
}
sub:provenance {
sub:assertion prov:generatedAtTime "2021-08-24T15:53:47.2920" .
}
sub:pubinfo {
sub:sig npx:hasAlgorithm "RSA";
npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCamPJb4SzqpLXn//XJ5dlVfzz6QI+RPmiJTLXF/by2JR7sHMKRsCQDFsYMlq8zGHghOIkjRP9dpLZUtZzUcHt3MXiFKEPo8eGzUe9p+JXKFC8xxkJr94z2vq6IdMf71Iu1GH8SeDAKt/DgYO4zNaw8VuXvxnZRewKZSA+u8zWPVwIDAQAB";
npx:hasSignature "Ls/zauvLpbfRhYdRIwdUmPe+S/Sz8Wecb4rRMHeP7+1mnE7/oyM34AF8fy8bNyQBIPfc4T1D8ezK2X30IZSdrRx8EMFv701bE0cBwK0BUUUNG/AQqSkhJ4JW0EpBS+ubbFENYEIi/woCmYMMf9YrbYjUrDRIq8maq6U18o7iFeg=";
npx:hasSignatureTarget this: .
this: dct:created "2021-09-13T13:14:11.326+02:00"^^xsd:dateTime;
dct:creator orcid:0000-0002-7641-6446;
npx:supersedes ;
prov:generatedAtTime "2021-08-24T15:53:47.2920";
prov:wasAttributedTo orcid:0000-0002-7641-6446;
ns1:wasCreatedFromProvenanceTemplate ;
ns1:wasCreatedFromPubinfoTemplate ,
, ;
ns1:wasCreatedFromTemplate .
}